Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with SBRT in Advanced Solid Tumors
NCT02608385Phase 1Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Dec 2015
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in solid tumor (advanced stage) (3 cohorts), sponsored by University of Chicago. Primary endpoint: Recommended stereotactic body radiotherapy (SBRT) dose in combination with pembrolizumab at 3 months. Started Dec 2015; status: active, not recruiting.
02
Drugs
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02608385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608385.